Low-cost, Non-dilutive Financing for Acquiring Commercial Stage Products: A Guide to Revenue Interest Financing

Featured Whitepaper | Royalty/Revenue Interest Capital

Low-cost, Non-dilutive Financing for Acquiring Commercial Stage Products: A Guide to Revenue Interest Financing

Does an undervalued biopharma company have an alternative to using equity or convertible debt? Are there alternatives to traditional term debt (which might fund only 50-75% of the acquisition price but can encumber all current and future assets)?

Learn more and read the white paper on RIF.

Open the document in the new window/tab.